An improved molecular inversion probe based targeted sequencing approach for low variant allele frequency

Author:

Biezuner Tamir1ORCID,Brilon Yardena1,Arye Asaf Ben2,Oron Barak1,Kadam Aditee1,Danin Adi1,Furer Nili1,Minden Mark D3,Hwan Kim Dennis Dong3,Shapira Shiran4,Arber Nadir4,Dick John5,Thavendiranathan Paaladinesh6,Moskovitz Yoni1,Kaushansky Nathali1,Chapal-Ilani Noa1,Shlush Liran I178ORCID

Affiliation:

1. Department of Immunology, Weizmann Institute of Science, Rehovot 761001, Israel

2. Department of Statistics and Operations Research, Tel Aviv University, Ramat Aviv, Israel

3. Princess Margaret Cancer Centre, University Health Network (UHN), Department of Medical Oncology & Hematology, Toronto, ON, Canada

4. Sourasky Medical Center Tel Aviv, Israel

5. Princess Margaret Cancer Centre, University Health Network (UHN), Department of Molecular Genetics, Toronto, ON, Canada

6. Department of Medicine, Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

7. Division of Hematology, Rambam Healthcare Campus, Haifa, Israel

8. Molecular Hematology Clinic Maccabi Healthcare Services, Tel Aviv, Israel

Abstract

Abstract Deep targeted sequencing technologies are still not widely used in clinical practice due to the complexity of the methods and their cost. The Molecular Inversion Probes (MIP) technology is cost effective and scalable in the number of targets, however, suffers from low overall performance especially in GC rich regions. In order to improve the MIP performance, we sequenced a large cohort of healthy individuals (n = 4417), with a panel of 616 MIPs, at high depth in duplicates. To improve the previous state-of-the-art statistical model for low variant allele frequency, we selected 4635 potentially positive variants and validated them using amplicon sequencing. Using machine learning prediction tools, we significantly improved precision of 10–56.25% (P < 0.0004) to detect variants with VAF > 0.005. We further developed biochemically modified MIP protocol and improved its turn-around-time to ∼4 h. Our new biochemistry significantly improved uniformity, GC-Rich regions coverage, and enabled 95% on target reads in a large MIP panel of 8349 genomic targets. Overall, we demonstrate an enhancement of the MIP targeted sequencing approach in both detection of low frequency variants and in other key parameters, paving its way to become an ultrafast cost-effective research and clinical diagnostic tool.

Funder

EU horizon 2020

LLS and rising tide foundation

ISF-NSFC

ISF-IPMP-Israel Precision Medicine Program

Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine

Sagol Institute for Longevity Research

Barry and Eleanore Reznik Family Cancer Research Fund

Steven B. Rubenstein Research Fund

Rising Tide Foundation

Applebaum Foundation

Princess Margaret Cancer Foundation

Publisher

Oxford University Press (OUP)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3